Berlition 600edu ampoules 600mg/24ml №5

injection

Composition

1 ampoule contains 600 U of thioctic (alpha-lipoic) acid

Packing

5 ampoules

Mechanism of action

Berlition is a drug that regulates metabolism. Thioctic (a-lipoic) acid, which is similar in pharmacological properties to Vitamins of group B, is formed endogenously by the oxidative decarboxylation of a-keto acids and pyruvic acid.
Participates in the regulation of lipid and carbohydrate metabolism, has a hepatoprotective, antioxidant and detoxification effect. Improves trophism of neurons.

Indications and usage

- diabetic polyneuropathy;
- alcoholic polyneuropathy.

Contraindications

- pregnancy;
- lactation (breastfeeding);
- hypersensitivity to the drug.

Dosage and administration

In severe forms of polyneuropathy at the beginning of treatment, the drug is prescribed in / in 300-600 mg each (respectively, 12-24 ml) per day for 2-4 weeks. In the future, they switch to maintenance therapy and prescribe 300 mg pills (1 tab.) 1 time per day.
For i / m administration, the dose administered at one injection site should not exceed 50 mg (2 ml). V / m administration of the drug in high doses should be carried out in the form of several injections (2 ml for each injection site).

Adverse reactions

With the rapid in / in the introduction of possible sensations of heaviness in the head and difficulty breathing, which pass on their own.
From the side of the central nervous system: in some cases, convulsions and diplopia were observed after intravenous infusion.
Hemic and lymphatic: in some cases, petechiae and thrombocytopathy were observed after intravenous administration.
Metabolism: hypoglycemia.
Allergic reactions: with a / in the introduction at the injection site may cause urticaria and the development of eczema; rarely, systemic allergic reactions up to anaphylactic shock. When you take the drug inside possible skin manifestations of allergic reactions.
Local reactions: sometimes - burning pain at the injection site.

Special notes

The results of recent clinical studies have shown a high efficacy of using thioctic (a-lipoic) acid for patients with type 2 diabetes with cardiovascular manifestations of diabetic neuropathy. The therapeutic effect of Berlithion in this group of patients may result from the effect of the drug on the autonomic nervous system, in particular by increasing the speed of wave propagation in the visceral parasympathetic and sympathetic fibers.
Use in pediatrics
Berlition cannot be prescribed to children and adolescents due to the lack of clinical experience with the drug in this category of patients.

Drug Interactions

In vitro, thioctic (a-lipoic) acid reacts with complexes containing metal ions (for example, cisplatin). Therefore, when taken simultaneously with Cisplatin, a weakening of the effect of Berlition is possible.
With simultaneous use of ethanol and its metabolites can lead to a weakening of the action of Berlition.
Berlithion enhances the hypoglycemic effect of insulin and oral hypoglycemic agents.
Pharmaceutical Interaction
Thioctic (a-lipoic) acid forms insoluble complex compounds with glucose molecules (including with solutions of levulose).
Berlition is incompatible with glucose solutions, Ringer's solution, as well as with solutions that are known to react with SH-groups or disulfide bridges.

Storage conditions

Store in a dry, cool, dark place.